Abstract
A major obstacle of testosterone (T) treatment in experimental animals is the difficulty of maintaining long-term physiologic/anabolic steady serum levels after exogenous T administration. In two complementary studies we investigated the pharmacokinetic properties of different T formulations in male rats.
Study I
Mature male Wistar rats (> 380 g, n = 4 - 7/group) were divided into four treatment groups: 1) sham-operated non orchiectomised (non-ORX) and placebo; 2) orchiectomised (ORX) and subcutaneous testosterone pellets (TP) (15, 25, 75 mg/60 days release or placebo pellets); 3) ORX and a single injection of testosterone undecanoate (TUD) (31, 62.5 or 125 mg/kg body weight subcutaneously (s.c.) or vehicle; 4) ORX and testosterone propionate (Tprop) (10, 20, 40 mg/month) or vehicle as a single injection s.c. Serum T was measured at baseline and in weekly intervals for 4 weeks.
Study II
Mature male Wistar rats (180 - 200 g) were randomly assigned to one of 5 experimental groups (n = 5 - 6/group): 1) normal untreated rats (controls); 2) ORX untreated rats, and non-ORX rats receiving one of three treatment options; 3) 250 mg/kg body weight TUD i.m. (TUD 250); 4) 500 mg/kg body weight TUD i.m. (TUD 500); 5) 100-mg testosterone pellet/90 days release s.c. (TP 100). Serum T was measured at baseline and in intervals for 6 weeks after T administration.
In both studies, the kinetic profile of TUD showed favourable continuous steady state levels over several weeks. In contrast, testosterone release by subcutaneous pellets resulted in a shorter than expected duration of elevated serum T levels with high inter-individual variability. Tprop administration led to only a short-lasting serum T increase with low serum T levels already 14 days after injection.
In conclusion, a single injection of TUD (100 mg/kg body weight s.c.) is effective in inducing physiological testosterone levels in ORX rats for a minimum of four weeks. High dose TUD (500 mg/kg body weight i.m.) given as a single injection results in supraphysiological anabolic testosterone concentrations for up to six weeks in non-ORX rats. TUD was superior to other T release preparations and represents a convenient and effective tool for T administration in experimental animals.
Key words
Testosterone - testosterone undecanoate - pellets - pharmacokinetic - testosterone propionate
References
-
1
Adams M R, Williams J K, Kaplan J R.
Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness.
Arteriscler Thromb Vasc Biol.
1995;
15
562-570
-
2
Alexandersen P, Haarbo J, Christiansen C.
The relationship of natural androgens to coronary heart disease in males: review.
Atherosclerosis.
1996;
25
1-13
-
3
Bagatell C J, Bremner W J.
Androgens in men: uses and abuses.
N Engl J Med.
1996;
334
707-714
-
4
Behre H M, Abshagen K, Oettel M, Hubler D, Nieschlag E.
Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.
Europ J Endocrinol.
1999;
140
414-419
-
5
Gill R K, Turner R T, Wronski T J, Bell N H.
Orchiectomy markedly reduces the concentration of the three isoforms of transforming growth factor beta in rat bone, and reduction is prevented by testosterone.
Endocrinology.
1998;
139
546-550
-
6
Hügel S, Reincke M, Stromer H, Winning J, Horn M, Dienesch C, Mora P, Schmidt H H, Allolio B, Neubauer S.
Evidence against a role of physiological concentrations of estrogen in post-myocardial infarction remodeling.
JACC.
1999;
34
1427-1434
-
7
Kwan M, Greenleaf W J, Mann J, Crapo L, Davidson J M.
The nature of androgen action on male sexuality; a combined laboratory self report study on hypogonodal men.
Endocrinology.
1983;
57
557-562
-
8
Notelovitz M.
Effects of estrogen/androgen therapy on bone mineral density parameters.
J Reprod Med.
2001;
46
325-331
-
9
Remmers D E, Cioffi W G, Bland K I, Wang P, Angele M K, Chaudry I H.
Testosterone: the crucial hormone responsible for depressing myocardial function in males after trauma hemorrhage.
Annals Surg.
1998;
227
790-799
-
10
Robaire B, Ewing L L, Irby D C, Desjardins C.
Interactions of testosterone and estradiol-17β on the reproductive tract of the male rat.
Biol Reproduct.
1979;
21
455-463
-
11
Snyder P J, Peachey H, Berlin J A, Hannoush P, Haddad G, Dlewati A, Santanna J, Loh L, Lenrow D A, Holmes J H, Kapoor S C, Atkinson L E, Strom B L.
Effects of testosterone replacement in hypogonadal men.
J Clin Endocrinol Metab.
2000;
85
2670-2677
-
12
Stratton L G, Ewing L L, Desjardin C.
Efficacy of testosterone-filled polydimethylsiloxane implants in maintaining plasma testosterone in rabbits.
J Reprod Fert.
1973;
35
235-244
-
13
Sun Y T, Wreford N G, Robertson D M, de Kretser D M.
Quantitative cytological studies of spermatogenensis in intact and hypophysectomized rats: identififcation of androgen-dependent stages.
Endocrinol.
1990;
127
1215-1223
-
14
Wang J, Wreford N GM, Lan H Y, Atkins R, Hedger M P.
Leukocyte populations of the adult rat testis following removal of the leydig cells by treatment with ethane dimethane sulfonate and subcutaneous testosterone implants.
Biol Reprod.
1994;
51
551-561
Dr. med. Frank Callies
Department of Endocrinology
Medical University Hospital
Josef-Schneider-Straße 2
97080 Wuerzburg
Germany
Phone: + 4993120136788
Fax: + 49 9 31 20 13 62 83
Email: Callies_F@medizin.uni-wuerzburg.de
